GTCR to Buy Drugmaker Zentiva from Advent in $4.8 Billion Deal

Buyout firm GTCR agreed to acquire generic drugmaker Zentiva Group ASfrom Advent, adding to a flurry of health-care deals this year.

The transaction is expected to be completed by early 2026, according to a statement on Thursday that confirmed an earlier Bloomberg News report. Zentiva is valued at about $4.8 billion in the transaction, people familiar with the matter have said.

Bloomberg News reported in November that Advent was working with Goldman Sachs Group Inc. and boutique adviser PJT Partners Inc. to explore a possible sale of Zentiva. TPG Inc. and India’s Aurobindo Pharma Ltd. also expressed interest ...